News

Captor Therapeutics Q1 2022 report: company continues to generate exciting data on lead projects (CT-01, CT-02, CT-03), maintains strong financial position

Captor Therapeutics to host R&D Day on May 18, 2022

Captor Therapeutics has released its 2021 report. Recent quarterly results have seen significant R&D progress; The Company has sufficient funds for further research and is meeting expenditures on schedule

Captor Therapeutics announces further robust in-vivo efficacy data from CT-01 TPD candidates for hepatocellular carcinoma

Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma

Captor Therapeutics invited to TPD panel at the 8th Annual LSX World Congress 2022

Captor Therapeutics named as the most innovative company on the WSE in the Stock Exchange Company of the Year ranking

Captor Therapeutics to Present at the 2nd Annual Targeted Protein Degradation Europe Summit 2022